Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, has made notable strides in its development of systemic oncolytic targeted immunotherapies, as detailed in a recent shareholder letter from CEO Eric Poma, PhD. The letter highlights the company’s transformative year, marked by operational streamlining and advancements in its RedTail platform, a systemically delivered virotherapy aimed at targeting metastatic cancers and delivering genetic payloads.
Under the leadership of Dr. Poma, appointed in April 2025, and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has presented preclinical data at prestigious conferences such as AACR and ASCO. These presentations showcased the RedTail platform’s tumor selectivity and immune modulation potential, sparking partnership discussions and enabling IND-enabling studies for the lead candidate, CLD-401. An Investigational New Drug (IND) filing for CLD-401 is anticipated by the end of 2026.
Furthermore, Calidi has initiated an IND for its intratumoral virotherapy, CLD-201, with Phase I trials expected to commence by the end of the year. The company’s financial health is robust, with $10.6 million in cash at the end of Q1 and a significantly reduced burn rate, positioning it well to accelerate its pipeline development while maximizing shareholder value.
Calidi Biotherapeutics’ innovative approach leverages proprietary stem cell-based platforms to deliver oncolytic viruses, offering promising avenues for treating high-grade gliomas and solid tumors. Its dual strategy not only aims to treat but also potentially prevent metastatic disease, representing a significant leap forward in oncology treatment.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp
. The source URL for this press release is Calidi Biotherapeutics Inc. Advances Oncolytic Immunotherapy Pipeline with Strategic Focus in 2025.